Treatment of persistent epithelial defects with single-dose autologous serum eye drops

2021 ◽  
pp. 112067212110483
Author(s):  
Selma Özbek-Uzman ◽  
Züleyha Yalnız-Akkaya ◽  
Evin Şingar Özdemir ◽  
Ayşe Burcu
Keyword(s):  
Single Dose ◽  
Healing Time ◽  
Autologous Serum ◽  
Eye Drops ◽  
Artificial Tears ◽  
Duration Of Treatment ◽  
The Mean ◽  
Preservative Free ◽  
Serum Eye Drops

Purpose: We aimed to investigate the efficacy and safety of single-dose autologous serum eye drops (ASEDs) for treatment of persistent corneal epithelial defects (PEDs). Methods: About 34 eyes of 26 patients treated from March 2016 to May 2020 with a single dose of ASEDs for PEDs that did not respond to conventional treatment were retrospectively evaluated. Patient demographics, predisposing factors, size, and duration of the PED, duration of treatment, and dosage of ASEDs, PED healing time, success rate of the ASED treatment, and follow-up time after the onset of ASED treatment were recorded. Autologous serum eye drops (20%) were prepared by diluting the serum with preservative-free artificial tears in single-dose vials. Vials were stored at −20°C and used daily after dissolving. Results: The mean patient age was 47.0 ± 18.5 years, and 13 (50%) of the patients were male. The most common indication for ASEDs was PED after keratoplasty. The mean duration of ASED treatment was 8.5 ± 6.3 months, and mean follow-up time was 22.8 ± 12.2 months. Autologous serum eye drop treatment was effective in 25 (73.5%) eyes and partially effective in 5 (14.7%) eyes. None of the eyes displayed complications related to the treatment. Conclusion: In patients with PED for whom conservative treatment is insufficient, ASEDs prepared by dilution with preservative-free artificial tears in single-dose vials and administered based on the daily use principle appear to be effective and safe.

scholarly journals APPLICATION OF AUTOLOGOUS SERUM EYE DROPS AFTER PTERYGIUM SURGERY

2021 ◽  
Vol 71 (5) ◽  
pp. 1563-66
Author(s):  
Hassan Sajjad Rathore ◽  
Ahsan Mukhtar ◽  
Shahzad Saeed ◽  
Umar Ijaz ◽  
Mamoona Javaid ◽  
...  
Keyword(s):  
Corneal Epithelium ◽  
Healing Time ◽  
Complete Healing ◽  
Autologous Serum ◽  
Military Hospital ◽  
Eye Drops ◽  
Cross Sectional ◽  
Conjunctival Inflammation ◽  
Pterygium Surgery ◽  
Serum Eye Drops

Objective: To compare the corneal epithelium healing time and post-operative pain after pterygium surgery with and without he use of autologous serum drops. Study Design: Comparative cross-sectional study. Place and Duration of Study: Eye Department, Combined Military Hospital Quetta, from Jan to Aug 2019. Methodology: Twenty patients were included in this study and divided into two groups. All patients underwent pterygium excision with conjunctival autograft. Fourteen of them were instilled with autologous serum drops while 14 were given lubricants postoperatively until corneal epithelium healed completely. Corneal epithelium healing time, visual analog scale for postoperative pain assessment, conjunctival inflammation and recurrences were evaluated. Patients were followed up for 6 months. Results: For corneal epithelial healing, 1 (7.14%) patient showed complete healing on day 2 while 7 (50%) showed healing on day 3 and 6 (42.86%) on day 4. While in non-autologous serum drops group 7 (50%) showed complete healing on day 4 while 4 (28.57%) showed healing on day 5 and 3 (21.43%) on day 6. The mean corneal healing time of autologous serum drops group was 3.36 ± 0.63 days and that of non-autologous serum drops group was 4.71 ± 0.83 days. Patients of autologous serum drops group also experienced significantly less pain as compared to the non-autologous serum drops group. While the recurrence rate and conjunctival inflammation in the two groups was found to be of equal degree. Conclusion: Patients who used autologous serum eye drops post operatively experienced less pain and their corneal epithelium healed earlier than the.......

scholarly journals Autologous serum eye-drops and enhanced epithelial healing time after photorefractive keratectomy

2017 ◽  
Vol 101 (1) ◽  
pp. 34-37 ◽  
Author(s):  
Hanife Tuba Akcam ◽  
Metin Unlu ◽  
Emine Esra Karaca ◽  
Hulya Yazici ◽  
Bahri Aydin ◽  
...  
Keyword(s):  
Healing Time ◽  
Photorefractive Keratectomy ◽  
Autologous Serum ◽  
Eye Drops ◽  
Serum Eye Drops ◽  
Epithelial Healing

scholarly journals The Efficacy of Topical 0.03% Tacrolimus Dermatologic Ointment in Treatment of Vernal Keratoconjunctivitis

2021 ◽  
Vol 2 (4) ◽  
pp. 6
Author(s):  
Muhammad Adnan ◽  
Amena Masrur ◽  
Furqan Ahmed Khan ◽  
Ali Tayyab
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Slit Lamp ◽  
Night Time ◽  
The Mean ◽  
Preservative Free

Objective: To determine the efficacy of 0.03% Tacrolimus dermatologic ointment in the treatment of Vernalkeratoconjunctivitis.Study Design: Cross-sectional.Place and Duration of Study: The study was conducted at Eye Donors Association Hospital, Wah Cantonmentfrom August 2019 to January 2020.Materials and Methods: 103 diagnosed patients ofvernal keratoconjunctivitis, aged 3-16 years, were includedin this study. They were treated with 0.03% Tacrolimus dermatologic ointment,applied in the inferior fornixonce at night time, for a period of two months. In addition, these patients were also prescribeda topical antihistamine(0.05 % ketotifen eye drops 3 times a day)and preservative free artificial tearsfor symptomatic relief.The patients were evaluated at 4 and 8 weeks after the initiation of treatment. At each follow up the clinicalsigns were assessed on a slit lamp biomicroscope by a single observer and recorded on a standardized gradingsheet.Results: Out of 103 patients, 66% were male and mean age was 9 years (range 3-16 years). The mean baselinescores showed a statistically significant decrease, with the exception of palpebral follicles & limbal Trantas dotsafter 8 weeks of treatment.Conclusion: 0.03% Tacrolimus dermatologic ointment was found to be safe and effective in the treatment ofvernal kerato-conjunctivitis.

Autologous Serum Containing Platelet Derived Growth Factors (PDGFs) as Topical Treatment for “Sicca Syndrome” Associated with Chronic GvHD.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2864-2864
Author(s):  
Del Fante Claudia ◽  
Perotti Cesare ◽  
Viarengo Gianluca ◽  
Marchesi Andrea ◽  
Parisi Cristina ◽  
...  
Keyword(s):  
Microbial Contamination ◽  
Therapeutic Option ◽  
Chronic Gvhd ◽  
Sicca Syndrome ◽  
Autologous Serum ◽  
Eye Drops ◽  
Schirmer’S Test ◽  
Single Use ◽  
Serum Eye Drops

Abstract Introduction: Severe “sicca syndrome” after haemopoietic stem cell transplantation impairs the quality of life of transplanted patients and no valid therapeutic options are available. Autologous serum enriched with PDGFs is a new therapeutic option because of its high content in different growth factors and fibronectin able to restore the epithelial integrity of cornea and conjunctive. Herein we present our experience on 16 allotransplanted patients (pts) undergoing extracorporeal photochemotherapy treatment for drug resistant chronic GvHD associated with severe eye dryness. All pts were treated with autologous serum eye drops prepared in our laboratory under gmp conditions. Material and Methods: A peripheral blood sample of 30 ml was obtained from each pt in sterile conditions and centrifuged at 1500 rpm per 15 min. Serum was diluted with sterile saline to obtain a final concentration of 30%. No antibiotic was added. The solution was aliquoted in 1 ml plastic tubes (with the purpose of single use) and freezed at −20°C. The maximum storage time allowed was 30 days. At time of preparation PDGFs (PDGF, TGF b1, VEGF, EGF, IGF) content was assessed by ELISA technique and bacterial and fungal contamination was tested. 16 pts (11 M, 5 F), median age 41 yrs (range: 14–61), median plt count 170x103/mL (range: 110–530), median Hct% 36 (32–46) were enrolled and instructed to instill two autologous serum eye drops per eye four times/day. A written informed consent was always obtained. Schirmer’s test was performed immediately before treatment and bi-monthly. The median follow up was 12,5 months (4–16). Results: 14/16 pts experienced a significative dry eye improvement that was mantained during the course of treatment. The need of topical therapy diminished progressively till two drops per eye once a day. The mean Schirmer’s test value improved from 1.5 to 4.6 mm/5 mins during the follow up. Neither microbial contamination on the samples tested nor oftalmic infectious episodes were documented. Conclusions: Autologous serum eye drops demonstrated to be a valid, safe and low cost new therapeutic option for treatment of “sicca syndrome” associated with chronic GVHD. Preparation under gmp conditions, storage in single use vials and detailed instructions to the patient demonstrated to be an effective approach to avoid the addition of antibiotic and microbial contamination of the solution.

scholarly journals Topical 100% Serum Eye Drops for Treating Corneal Epithelial Defect after Ocular Surgery

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Kaevalin Lekhanont ◽  
Passara Jongkhajornpong ◽  
Lulin Choubtum ◽  
Varintorn Chuckpaiwong
Keyword(s):  
Complete Healing ◽  
Autologous Serum ◽  
Eye Drops ◽  
Epithelial Defect ◽  
Ocular Surgery ◽  
Corneal Epithelial ◽  
Corneal Epithelial Defect ◽  
Conventional Medical Therapy ◽  
Serum Eye Drops

The purpose of this study was to investigate the efficacy and safety of topical 100% serum eye drops for corneal epithelial defect after ocular surgery. A total of 181 patients who received topical 100% serum therapy for the treatment of corneal epithelial defect following several different types of ocular surgery were recruited into this study. Each patient already failed conventional medical therapy before being prescribed 100% serum eye drops. Slit-lamp biomicroscopic examination with fluorescein staining was performed at baseline and all follow-up visits. The main outcome measures were the rate of complete healing of the corneal epithelial defect and incidence of adverse events. One hundred and seventy-eight eyes (98.34%) received autologous serum eye drops, and 3 (1.66%) received allogeneic serum eye drops. The overall success rate of treating persistent postoperative epithelial defect using 100% serum eye drops was 93.92% (95% CI 0.88–0.98). The median time to complete corneal epithelialization was 4 days (95% CI 4-5). Adverse reactions were observed in 3 patients (1.66%), including sticky sensation with minimal eye discomfort and asymptomatic trace corneal subepithelial infiltration. No serious complications were reported. In conclusion, 100% serum eye drops are effective, safe, and tolerable for treating postoperative corneal epithelial defect following ocular surgeries.

Pilonidal Sinus: How to Choose Between Excision and Open Granulation Versus Excision and Primary Closure?

Swiss Surgery ◽  
2002 ◽  
Vol 8 (6) ◽  
pp. 255-258 ◽  
Author(s):  
Perruchoud ◽  
Vuilleumier ◽  
Givel
Keyword(s):  
Hospital Stay ◽  
Pilonidal Sinus ◽  
Primary Closure ◽  
Average Length ◽  
Length Of Hospital Stay ◽  
Healing Time ◽  
Incision And Drainage ◽  
The Mean ◽  
Primary Healing

Aims: The purpose of this study was to evaluate excision and open granulation versus excision and primary closure as treatments for pilonidal sinus. Subjects and methods: We evaluated a group of 141 patients operated on for a pilonidal sinus between 1991 and 1995. Ninety patients were treated by excision and open granulation, 34 patients by excision and primary closure and 17 patients by incision and drainage, as a unique treatment of an infected pilonidal sinus. Results: The first group, receiving treatment of excision and open granulation, experienced the following outcomes: average length of hospital stay, four days; average healing time; 72 days; average number of post-operative ambulatory visits, 40; average off-work delay, 38 days; and average follow-up time, 43 months. There were five recurrences (6%) in this group during the follow-up period. For the second group treated by excision and primary closure, the corresponding outcome measurements were as follows: average length of hospital stay, four days; average healing time, 23 days; primary healing failure rate, 9%; average number of post-operative ambulatory visits, 6; average off-work delay, 21 days. The average follow-up time was 34 months, and two recurrences (6%) were observed during the follow-up period. In the third group, seventeen patients benefited from an incision and drainage as unique treatment. The mean follow-up was 37 months. Five recurrences (29%) were noticed, requiring a new operation in all the cases. Discussion and conclusion: This series of 141 patients is too limited to permit final conclusions to be drawn concerning significant advantages of one form of treatment compared to the other. Nevertheless, primary closure offers the advantages of quicker healing time, fewer post-operative visits and shorter time off work. When a primary closure can be carried out, it should be routinely considered for socio-economical and comfort reasons.

scholarly journals Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases

Vision ◽  
2021 ◽  
Vol 5 (3) ◽  
pp. 34
Author(s):  
Ronald M. Sánchez-Ávila ◽  
Edmar Uribe-Badillo ◽  
Carlos Fernández-Vega González ◽  
Francisco Muruzabal ◽  
Borja de la Sen-Corcuera ◽  
...  
Keyword(s):  
Growth Factors ◽  
Corneal Ulcer ◽  
Disease Index ◽  
Eye Drops ◽  
Analog Scale ◽  
Ocular Surface Disease Index ◽  
Corneal Ulcers ◽  
Corrected Visual Acuity ◽  
The Mean

This study aimed to investigate the use of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers. RGTA treatment was applied (one drop every two days); however, if ulcer closure was not achieved, PRGF eye drops treatment was added (four times/day). The time taken to reach the ulcer closure, the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in terms of frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. Seventy-four patients (79 eyes) were included, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder (n = 27, 34.2%), mainly for herpes virus (n = 15, 19.0%). The time of PRGF eye drops treatment associated with the RGTA matrix was 4.2 ± 2.2 (1.5–9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved from the baseline (p < 0.001), and IOP remained unchanged (p = 0.665). RGTA and PRGF in noninfectious ulcers were effective and could be a therapeutic alternative for this type of corneal disease.

Hand Infections: An Audit of 160 Infections Treated in an Accident and Emergency Department

1993 ◽  
Vol 18 (1) ◽  
pp. 115-118 ◽  
Author(s):  
J. STEVENSON ◽  
I. W. R. ANDERSON
Keyword(s):  
Emergency Department ◽  
Complete Resolution ◽  
Wound Care ◽  
Duration Of Treatment ◽  
Mean Delay ◽  
Accident And Emergency ◽  
Accident And Emergency Department ◽  
The Mean ◽  
Careful Assessment

160 consecutive hand infections presented to an Accident and Emergency department over a four-month period. All but one were treated solely on an out-patient basis. The mean delay to presentation was three days, the mean duration of treatment was six days. Follow-up to complete resolution was achieved in 89% of cases. No patients were treated with parenteral antibiotics. The need for careful assessment, early aggressive surgery, and meticulous attention to the principles of wound care by experienced clinicians is emphasized.

scholarly journals Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
Maria Rosaria De Pascale ◽  
Michele Lanza ◽  
Linda Sommese ◽  
Claudio Napoli
Keyword(s):  
Human Serum ◽  
Clinical Studies ◽  
Tear Film ◽  
Eye Drops ◽  
Corneal Epithelial ◽  
Activated Platelets ◽  
Open Debate ◽  
Potential Benefits ◽  
Serum Eye Drops

Human serum contains a physiological plethora of bioactive elements naturally released by activated platelets which might have a significant effect on the regeneration of corneal layers by stimulating the cell growth. This mechanism supported the use of human serum eye drops in some ocular diseases associated with dystrophic changes and alterations of the tear film, such as persistent corneal epithelial defects and dry eye syndrome. We focused our effort on potential benefits and limitations of the use of human serum eye drops when conventional therapies failed. We reviewed the recent literature by reporting published studies from 2010 to 2014. Despite the limited evaluated study populations, most of the clinical studies have confirmed that serum eye drop therapy is effective in corneal healing by reducing ocular symptom, particularly during the short-term follow-up. In addition, three recent published studies have shown the efficacy of the serum eye drop therapy in comparison to traditional ones in intractable patients. Besides, reported ongoing clinical studies confirmed the open debate regarding the use of biologic tools for cornea regeneration. Results from these studies might open novel challenges and perspectives in the therapy of such refractory patients.

Sign in / Sign up

Export Citation Format

Share Document